The company has shifted from COVID-19 testing toward a future anchored in metabolic health and consumer-facing biowearables, solidifying its position as a defensive growth stock. The FreeStyle Libre platform is Abbott's crown jewel—the Libre 3 is the world's most widely used Continuous Glucose Monitor, on track to reach $10 billion in annual revenue by 2028. Abbott announced an agreement to acquire Exact Sciences, positioning the company to enter and lead in the fast-growing cancer diagnostics market, with transaction expected to close in Q2 2026.
Cyborg Score Rationale
Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index. The company delivered double-digit EPS growth in 2025 while expanding margins and launching significant new products. Abbott projects full-year 2026 organic sales growth of 6.5% to 7.5%, demonstrating resilient growth despite near-term diagnostics headwinds.
Top Insights
GLP-1 users are more likely to use Abbott's CGMs to manage their diets and monitor drug effects, creating a positive tailwind rather than competitive threat
CGM sales exceeded $7.5 billion in 2025, marking the third consecutive year of adding more than $1 billion in sales
Lingo, an over-the-counter biowearable launched in mid-2024, targets the wellness market and moves Abbott into direct competition with tech giants like Apple rather than traditional medical rivals
Adjusted operating margin expanded 150 basis points year-over-year to 25.8%, with expectations to maintain margin expansion of 50-70 basis points annually
Named Competitors
Medtronic Devices — Cardiovascular and diabetes devices
Apple Watch/Health — Consumer health tracking and biowearables
Insulin & GLP-1 Drugs — Diabetes and weight-loss pharmaceuticals
Nutrition Products — Clinical and consumer nutrition
Recent Developments
(January 2026) Abbott announced CE Mark approval for TactiFlex Duo Ablation Catheter to treat atrial fibrillation
(December 2025) FDA approval for Volt PFA System, Abbott's first pulsed field ablation offering in the United States
(November 2025) Abbott announced agreement to acquire Exact Sciences for entry into cancer diagnostics market
Open the full interactive Abbott Laboratories report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.